AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 4.2
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established between 1700 ₹ and 1735 ₹, utilizing the current resistance level as a trigger. An exit strategy would target the 20-day moving average at 1620 ₹ or potentially a pull back to the 1441 ₹ DMA 200 level if momentum stalls. Overall, the stock shows considerable strength and is trending upwards with consistent volume – it’s a buy for tactical traders looking for short-term gains, but with an emphasis on monitoring support levels.
✅ Positive
The stock is currently trading near a 52-week high, supported by recent USFDA approval for an inhalation aerosol product which typically generates positive momentum. Furthermore, the robust quarterly profit growth (31.8%) indicates strong operational performance and may be attracting investor interest.
⚠️ Limitation
Despite the positive indicators, the elevated P/E ratio (38.4 vs 34.8 Industry PE) suggests a premium valuation that could limit upside potential if earnings do not continue to outpace expectations. Volatility remains a risk given the current price levels and relatively high RSI reading of 63.2.
📈 Company Positive News
The USFDA approval for the inhalation aerosol product is a positive catalyst, reinforcing the company's regulatory compliance and expanding its market reach.
🏭 Industry
The pharmaceutical sector, particularly generic drug manufacturers like Aurobindo Pharma, remains attractive due to sustained demand, pricing pressures, and opportunities for expansion in regulated markets. However, competition within this sector can be intense.